Stanford Regulating Circuits of the Brain Study- Ketamine
NCT03475277 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13
Last updated 2026-01-02
Summary
This study is a biomarker study designed to characterize how ketamine impacts the reward circuits of the human brain.
Conditions
- Healthy
Interventions
- DRUG
-
Acute administration
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH - lead OTHER
Principal Investigators
-
Leanne M Williams, PhD · Study PI
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-08-19
- Primary Completion
- 2022-11-30
- Completion
- 2024-07-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents
NCT03748875 ·Status: UNKNOWN ·Phase: NA
-
A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants
NCT03808259 ·Status: COMPLETED ·Phase: PHASE1
-
Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine
NCT04156035 ·Status: COMPLETED ·Phase: NA
-
Brain Function in Response to Motivational Stimuli
NCT00047866 ·Status: COMPLETED
-
Ketamine for Low Mood States in the ER
NCT01209845 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
NCT05379959 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects
NCT04173962 ·Status: COMPLETED ·Phase: PHASE2
-
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
NCT04199468 ·Status: COMPLETED ·Phase: PHASE1
-
Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder
NCT03537950 ·Status: COMPLETED ·Phase: NA
-
Use of Ketamine in Severe Pain Syndromes
NCT06537375 ·Status: COMPLETED
-
Cannabinoid Control of Fear Extinction Neural Circuits in Humans
NCT02472847 ·Status: COMPLETED ·Phase: PHASE4
-
Ketamine IV Classic Protocol : Five Years Follow up
NCT04824157 ·Status: COMPLETED
-
Effects of Hallucinogens and Other Drugs on Mood and Performance
NCT02033707 ·Status: COMPLETED ·Phase: PHASE1
-
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
NCT04178993 ·Status: COMPLETED ·Phase: PHASE1
-
Endogenous Opioid Modulation by Ketamine
NCT03051945 ·Status: WITHDRAWN ·Phase: PHASE3
-
N-acetylcysteine and NMDA Antagonist Interactions
NCT00611897 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
NCT01794975 ·Status: COMPLETED ·Phase: PHASE1
-
Acute Dose-dependent Effects of DMT in Healthy Subjects
NCT05384678 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of Medication on Functional Connectivity
NCT03612713 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain
NCT00899600 ·Status: COMPLETED ·Phase: NA
-
Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
NCT04716335 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Network-Level Effects of Nitrous Oxide in the Human Brain
NCT03435055 ·Status: COMPLETED ·Phase: PHASE4
-
A First Study in Healthy Volunteers of a New Mobile Phone Application Measuring the Eyes Before and After Medication
NCT05731999 ·Status: COMPLETED ·Phase: NA
-
Neuroprotection by Cannabinoids in Huntington's Disease
NCT01502046 ·Status: COMPLETED ·Phase: PHASE2
-
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
NCT06624137 ·Status: RECRUITING